MedPath

Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction

Not Applicable
Conditions
Refractive Errors
Vision Disorders
Interventions
Device: EQ103
Registration Number
NCT04693247
Lead Sponsor
EyeQue Corp.
Brief Summary

This study is exploratory and examines whether the best-corrected visual acuities (BCVA's) from trial frames created with the refraction results obtained from a novel handheld optical device yields results similar to the ophthalmic refraction obtained from an autorefractor in healthy volunteers age stratum of 18 through 65 years.

Detailed Description

This study is exploratory and examines whether the best-corrected visual acuities (BCVA's) from trial frames created with the refraction results obtained from a novel handheld optical device yields results similar to the ophthalmic refraction obtained from an autorefractor in healthy volunteers age stratum of 18 through 65 years.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
35
Inclusion Criteria
  • Male or Female
  • Ages =>18 y.o. and =<65 y.o.
  • Binocular vision
  • Willing and able to give informed consent and follow all study procedures and requirements
  • Fluent in English
Exclusion Criteria
  • Has been diagnosed within 4 weeks, or currently has signs or symptoms, of COVID-19.
  • Has traveled outside the country within the last 4 weeks.
  • At the discretion of the investigator: Age strata has achieved minimum evaluable population.
  • Spherical correction > +8 or < -10
  • Using anticholinergic medications (including first-generation antihistamines) or other medications known to affect visual acuity within the greater of 3 days or 5 half-lives prior to enrolling in this study
  • Using an investigational drug or approved therapy for investigational use within the greater of 3 days or 5 half-lives prior to enrolling in this study
  • Has initiated any new medication in the past 2 weeks that, in the best medical judgment of the investigator, would impact their participation in the study or ability to use the EyeQue EQ103 device
  • Any self-reported mental illness or condition, including but not limited to:

claustrophobia, fear of simulators, nyctophobia.

  • Any self-reported neurological diseases, including but not limited to: epilepsy, Alzheimer's, nystagmus

Per subject self-reporting: eye disease, including but not limited to:

  • Glaucoma
  • Cataracts
  • Macular degeneration
  • Eye infection (by self-report or observation)
  • Keratoconus
  • Diabetic neuropathy/retinopathy
  • Cytomegalovirus retinitis
  • Color blindness (any color deficiency)
  • Diabetic macular edema
  • Amblyopia
  • Chronic or acute uveitis
  • Strabismus
  • Astigmatism > 3 diopters
  • Macular hole

Subjects that:

  • Lack physical dexterity to properly operate the EyeQue device.
  • Lack the ability to follow instruction
  • Lack a command of the English language
  • Lack binocular vision
  • Are colorblind
  • Had eye surgery within the last 12 months (including Lasik)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Refraction with a Hand-held Refraction DeviceEQ103This is the device that will be compared to a standard device.
AutorefractorEQ103Standard Device
Primary Outcome Measures
NameTimeMethod
Best corrected visual acuity (BCVA) for both eyes EQ103 vs Autorefractor for all participantsDay 1

Tendency of, or achieving, statistical non-inferiority of EyeQue EQ103 BCVA's (reading an EDTRS chart) for each eye from (pooled) trial frames created with the refraction values compared with those of an autorefractor analyzed with all age groups.

Secondary Outcome Measures
NameTimeMethod
Best corrected visual acuity (BCVA) for worse eye: EQ103 vs Autorefractor for all subjects and age groupingsDay 1

Tendency of, or achieving, statistical non-inferiority of EyeQue EQ103 BCVA's (reading an EDTRS chart for worse eye from trial frames created with the refraction values compared with those of an autorefractor analyzed within the following age strata.

o Age Groups: All, 18 - 29, 30 - 44, 45 - 65

Best corrected visual acuity (BCVA) for both eyes EQ103 vs Autorefractor examining age groupingsDay 1

Tendency of, or achieving, statistical non-inferiority of EyeQue EQ103 BCVA's (reading an EDTRS chart for each eye (pooled) from trial frames created with the refraction values compared with those of an autorefractor analyzed within the following age strata.

o Age Groups: 18 - 29, 30 - 44, 45 - 65

Trial Locations

Locations (1)

EyeQue

🇺🇸

Newark, California, United States

© Copyright 2025. All Rights Reserved by MedPath